Antimicrobial Therapy with Ceftazidime and Piperacillin/Tazobactam

Spectrum of Activity and Clinical Implications

Ceftazidime has poor activity against gram-positive cocci, including viridans streptococci, coagulase-negative staphylococci, and methicillin-resistant S. aureus, according to the Clinical Infectious Diseases guidelines 1
Piperacillin/tazobactam is recommended as single-agent therapy for intra-abdominal infections without requiring metronidazole, as stated by the Praxis Medical Insights guidelines, but also supported by other sources 2
Ceftazidime has no anaerobic activity and requires metronidazole addition for infections involving anaerobes, as reported in the World Journal of Emergency Surgery 3, 4

Extended use of cephalosporins, including ceftazidime, should be discouraged due to selective pressure for ESBL-producing Enterobacteriaceae, according to the World Journal of Emergency Surgery 3
De-escalation to monotherapy should occur within 3-5 days once clinical improvement is evident and culture results are available, as recommended by the Intensive Care Medicine and World Journal of Emergency Surgery guidelines 3, 5

Using ceftazidime for intra-abdominal infections without adding metronidazole for anaerobic coverage is a common pitfall, as warned by the World Journal of Emergency Surgery and Praxis Medical Insights guidelines 2, 3, 4
Combining two β-lactams, such as ceftazidime and piperacillin/tazobactam, provides no mechanistic advantage when the goal is synergy, and a β-lactam plus aminoglycoside should be used instead, as stated by the Intensive Care Medicine and Clinical Infectious Diseases guidelines 1, 5

The Infectious Diseases Society of America recommends limiting the use of extended-spectrum cephalosporins, including ceftazidime, to targeted pathogen therapy in settings with high incidence of ESBL-producing Enterobacteriaceae, due to the selective pressure that leads to the emergence of resistance 6
The use of extended-spectrum cephalosporins should be minimized and limited to targeted pathogen therapy 6
For infections caused by carbapenem-resistant Enterobacteriaceae (CRE) producing metallo-beta-lactamases (MBL), the combination of ceftazidime/avibactam plus aztreonam is strongly recommended, showing significantly lower 30-day mortality (19.2% vs 44%) compared to other in vitro active antibiotics 7
Ceftazidime/avibactam is suggested for treating infections caused by CRE producing serine carbapenemase, including KPC and OXA-48, which may be more effective than other antibacterial therapies 8

Ceftazidime provides strong activity against gram‑negative organisms, especially Pseudomonas aeruginosa, making it the primary agent for infections caused by this pathogen. 9